Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

642
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
642
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

669
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
669
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.5K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.5K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.0K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.0K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

945
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
945

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPD.

Chest·2023
Same author

Medical knowledge about COVID-19 is travelling at the speed of mistrust: why this is relevant to primary care.

Family practice·2022
Same author

Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade.

Journal of global health·2021
Same author

Perceptions, attitudes, and behaviors of short-acting beta<sub>2</sub> agonist users: an Australian cross-sectional community pharmacy-based study.

The Journal of asthma : official journal of the Association for the Care of Asthma·2020
Same author

Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design.

ERJ open research·2020
Same author

Glycemic Improvement Using Continuous Glucose Monitoring by Baseline Time in Range: Subgroup Analyses from the DIAMOND Type 1 Diabetes Study.

Diabetes technology & therapeutics·2020

Related Experiment Video

Updated: Dec 29, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.3K

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD.

Anthony D'Urzo1, Kenneth R Chapman2, James F Donohue3

  • 1Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. tonydurzo@sympatico.ca.

Pulmonary Therapy
|February 7, 2020
PubMed
Summary

Fixed-dose combinations of long-acting bronchodilators are key for COPD. This review compares inhaler devices for these treatments, aiding physician choice for optimal patient outcomes.

Keywords:
BronchodilationChronic obstructive pulmonary diseaseCombination bronchodilator agentsInhalersLABALAMAPharmacotherapy

More Related Videos

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

8.0K
Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.3K

Related Experiment Videos

Last Updated: Dec 29, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.3K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

8.0K
Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.3K

Area of Science:

  • Pulmonology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Fixed-dose combinations (FDCs) of long-acting β-agonist (LABA) and long-acting muscarinic antagonist (LAMA) are central to symptomatic COPD maintenance therapy.
  • Inhaler devices are crucial for LABA/LAMA FDC effectiveness, with guidelines recommending regular assessment of patient technique.
  • Patient preferences and adherence to inhaler devices significantly influence optimal COPD disease control.

Purpose of the Study:

  • To objectively examine and compare major inhaler devices for LABA/LAMA FDCs.
  • To discuss inhaler characteristics affecting airway drug deposition and patient handling.
  • To provide an evidence-based framework for selecting optimal inhaled therapy for COPD, focusing on devices.

Main Methods:

  • Systematic review and comparative analysis of available literature on inhaler devices for LABA/LAMA FDCs.
  • Evaluation of device characteristics influencing drug delivery and patient interaction.
  • Synthesis of data on real-world patient preferences and adherence.

Main Results:

  • Comparison of different inhaler device types used for LABA/LAMA FDCs.
  • Identification of key device features impacting lung deposition and clinical outcomes.
  • Discussion of factors influencing patient preference and handling of inhaler devices.

Conclusions:

  • Inhaler device choice is critical for the efficacy of LABA/LAMA FDCs in COPD management.
  • Understanding device characteristics and patient factors is essential for optimizing inhaled therapy.
  • This review offers guidance to physicians navigating the complexities of COPD inhaled treatments and device selection.